FindTrial
Sign In

Research of molecular basis of delayed asexual parasite clearance times in treatment of Plasmodium falciparum malaria with dihydroartemisinin-piperaquine in Yunnan and neighboring areas of other countries

Research of molecular basis of delayed asexual parasite clearance times in treatment of Plasmodium falciparum malaria with dihydroartemisinin-piperaquine in Yunnan and neighboring areas of other countries

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17012524
Enrollment
Unknown
Registered
2017-09-01
Start date
2017-10-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malaria

Interventions

Group of DHA-PPQ sensitivity surveillance:DHA-PPQ

Sponsors

Yunnan Institute of Parasitic Diseases
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Microscopy- confirmed patients with monoinfections of P. falciparum; 2. Aged 1–65 years; 3. Asexual parasite density =500 parasites/ul.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Having taken any anti-malarial drug within the past 14 days; 3. History of hypersensitivity to any of the study drugs; 4. Severe dysfunction of kidney, liver and heart; 5. Severe malaria such as cerebral malaria, hyper body temperature (>41 degree C); 6. Unable to follow up.

Design outcomes

Primary

MeasureTime frame
Parasite clearance times;Fever clearance times;ring-stage survival rate;—

Countries

Myanmar

Contacts

Public ContactHui LIU

Yunnan Institute of Parasitic Diseases

liubible@126.com+86 15308796079

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026